GlassScriptPhysician profile
Celina Maria Moore
NPI 1972684967
$970.37
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $99.37 · 2021: $63.86 · 2022: $175 · 2023: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $400.90 | 2019-2023 | Bexsero |
| Cranial Technologies, INC | $117.76 | 2019-2023 | Doc Band |
| Sanofi Pasteur INC. | $91.74 | 2022-2023 | |
| Genentech USA, INC. | $59.64 | 2019 | |
| Pfizer INC. | $57.47 | 2020-2023 | |
| Alk-Abello, INC | $56.54 | 2023 | Grastek, Ragwitek, Odactra |
| Seqirus USA INC | $42.78 | 2022-2023 | Flucelvax Quadrivalent |
| Phadia US INC. | $25.08 | 2023 | Immunocap |
| Abbvie INC. | $24.81 | 2019 | |
| Merck Sharp & Dohme LLC | $23.06 | 2019-2021 | |
| Shire North American Group INC | $19.61 | 2019 | |
| Corium, LLC | $19.45 | 2023 | Azstarys |
| Qol Medical, LLC | $16.24 | 2020 | |
| Neos Therapeutics, LP | $15.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celina Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.